3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
6
Lymphoid
6
Myeloid
1
Conditions
Primary Myelofibrosis
7
Neoplasms
5
Myeloproliferative Disorders
2
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Thrombocythemia, Essential
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycythemia Vera
1
Leukemia, Myelomonocytic, Chronic
1
Interventions
Cyclophosphamide
162
fludarabine phosphate
127
Mycophenolic Acid
96
Tacrolimus
92
Whole-Body Irradiation
85
Busulfan
85
Peripheral Blood Stem Cell Transplantation
82
fludarabine
79
Cyclosporine
68
Melphalan
63
Antilymphocyte Serum
58
Filgrastim
56
Methotrexate
55
Thiotepa
39
Radiotherapy
39
Cord Blood Stem Cell Transplantation
34
Granulocyte Colony-Stimulating Factor
29
Cytarabine
28
Methylprednisolone
27
Stem Cell Transplantation
26
Sirolimus
24
thymoglobulin
23
Etoposide
23
Clofarabine
22
Rituximab
19
Flow Cytometry
15
Cyclosporins
15
sargramostim
13
Specimen Handling
13
Alemtuzumab
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
navitoclax
×
Myeloid
×
Clear all
NCT03592576
2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available